News & Perspective

May 17, 2019

May 17, 2019

ASP Scan (Weekly) for May 17, 2019

Northern Ireland AMR plan
Rapid susceptibility tests
Unnecessary abx for respiratory infections
Antibiotics in school beef
UK veterinary stewardship policy
Improper prescribing in seniors
Resistant TB testing in China
Antibiotic production partnership
MCR-1 in chickens, camels
New CARB-X funding
Grant for TB research

Jan 18, 2019

Jan 18, 2019

ASP Scan (Weekly) for Jan 18, 2019

New CARB-X funding
VRE in Swiss hospitals
Antibiotic overprescribing in tots
Fast track for new C diff drug
Stewardship in pediatric surgery
MRSA decline in Germany
Antibiotic resistance on pig farms
Resistance genes in Bolivian river
Stewardship in English hospitals
Whiff of C diff in pets
Fecal microbiota transplant trial

Aug 21, 2014

Aug 21, 2014

News Scan for Aug 21, 2014

Controlling MRSA
Marburg virus drug trial
Vaccine-linked polio in Texas
A new animal model for MERS

Jul 28, 2015

Jul 28, 2015
MERS virus

New Saudi MERS case as teams publish animal studies

South Korea's government considers the hospital-linked outbreak over, as researchers reported on early vaccine and antibody findings.

Jul 29, 2011

Jul 29, 2011

Study: Antibody binds to all influenza A subtypes

(CIDRAP News) – A team of European researchers reported yesterday the discovery of a human monoclonal antibody that binds to all types of influenza A viruses, raising the prospect of a new flu treatment and improving the chances of developing a broadly protective or "universal" flu vaccine.

Jan 14, 2011

Jan 14, 2011

Antibodies from H1N1 patients raise hope for more versatile flu vaccines

(CIDRAP News) – A team of US researchers reported this week that a set of antibodies derived from 2009 H1N1 influenza patients showed an ability to react with a number of other flu strains, strengthening hopes that it will eventually be possible to create a broadly protective flu vaccine.

Nov 24, 2009

Nov 24, 2009

Novartis unveils US cell-based flu vaccine plant

(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»